Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGSTU:D8Y -0.85%39 EV-to-FCF is 46.08 as of Aug. 11, 2026, which is 4% below its 10-year median of 47.78. GuruFocus rates STU:D8Y with a GF Score™ of 39/100 and a GF Value™ of €51.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 564 Drug Manufacturers companies, Sandoz Group AG ranks worse than 72.34% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sandoz Group AG's Enterprise Value is €37,761 Mil.
Sandoz Group AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €819 Mil. Therefore, Sandoz Group AG's EV-to-FCF for today is 46.08.
The historical rank and industry rank for Sandoz Group AG's EV-to-FCF or its related term are showing as below:
STU:D8Y'
s EV-to-FCF Range Over the Past 10 Years
Min: -90.1 Med: 47.78 Max: 536.62
Current: 46.34
During the past 4 years, the highest EV-to-FCF of Sandoz Group AG was 536.62. The lowest was -90.10. And the median was 47.78.
STU:D8Y's EV-to-FCF is ranked worse than 72.34% of 564
companies
in the Drug Manufacturers industry
Industry Median: 21.825
vs STU:D8Y: 46.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sandoz Group AG's PE Ratio (TTM) for today is calculated as:
Sandoz Group AG's share price for today is €77.16.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €1.259.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sandoz Group AG EV-to-FCF Related Terms
Sandoz Group AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's EV-to-FCF falls into.
Sandoz Group AG's current Enterprise Value is €37,761 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €819 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (STU:D8Y) has a EV-to-FCF of 46.08 as of Aug. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sandoz Group AG and its competitors. This is near median its historical median of 47.78. According to the industry distribution chart, Sandoz Group AG ranks #408 out of 564 companies in the Drug Manufacturers industry, placing it in the top 72.3%.
Is Sandoz Group AG's EV-to-FCF too high?
Sandoz Group AG's current EV-to-FCF of 46.08 is near median its 10-year median of 47.78. The Drug Manufacturers industry median EV-to-FCF is 21.83. Sandoz Group AG's value of 46.08 is 111.1% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #408 out of 564 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #408 out of 564 companies for EV-to-FCF. This places Sandoz Group AG in the lower half of its industry. The industry median EV-to-FCF is 21.83. Sandoz Group AG's value of 46.08 is 111.1% above this benchmark. While the company's 10-year median is 47.78 vs. the industry median of 21.83, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.83, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current EV-to-FCF of 46.08 is 111.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current EV-to-FCF is 46.08, which is near median its own 10-year median of 47.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (STU:D8Y) is currently considered Significantly Overvalued. The stock's GF Value™ is €51.27, compared to a current price of €77.16 — trading 50.5% above its estimated fair value. The current EV-to-FCF is 46.08, which is near median its 10-year median of 47.78 and 111.1% above the Drug Manufacturers industry median of 21.83. Sandoz Group AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sandoz Group AG (STU:D8Y), the current EV-to-FCF is 46.08 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (STU:D8Y) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of €77.16 is trading 50.5% above its estimated GF Value™ of €51.27.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for STU:D8Y:
EV-to-FCF: 46.08 (near median its 10-year median of 47.78)
GF Value™: €51.27 vs. price of €77.16 (50.5% above fair value)
Industry Position: 111.1% above the Drug Manufacturers median (#408 of 564)
No single metric tells the full story. See the STU:D8Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
39GF Score
Get the complete analysis for STU:D8Y
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:D8Y has been successfully added to your 
